Lupin, a global pharmaceutical giant, proudly announces the reception of the Establishment Inspection Report (EIR) from the United States Food and Drug Administration (U.S. FDA) for its manufacturing facility in Aurangabad. Conducted from March 6 to March 15, 2024, the…
Moderna, Inc. (NASDAQ: MRNA) has announced a significant milestone in its global efforts to combat COVID-19 by securing a contract with Brazil’s Ministry of Health (Ministério da Saúde). The contract entails supplying Moderna’s mRNA COVID-19 vaccine as a crucial component…
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) has unveiled significant progress in its suzetrigine pain program, potentially introducing the first new class of medication for acute and neuropathic pain in over twenty years. Suzetrigine, an oral selective NaV1.8 pain signal inhibitor (previously…
Novartis has revealed findings from the ALITHIOS open-label extension study, demonstrating the sustained efficacy of continuous Kesimpta® (ofatumumab) treatment for up to six years in individuals recently diagnosed with relapsing multiple sclerosis (RMS). These individuals, termed “treatment-naïve,” initiated treatment within…
Today marked a significant milestone in healthcare as the World Health Organization (WHO) unveiled the Patient Safety Rights Charter during the Global Ministerial Summit on Patient Safety. This groundbreaking Charter, the first of its kind, delineates patients’ rights within the…
Merck’s Curiosity Cube Hits the Road: Inspiring 45,000 Students Across 14 Countries Merck, a global leader in science and technology, has launched its 2024 Curiosity Cube tour from Darmstadt, Germany, marking the beginning of a journey to engage and educate…
Modalis Therapeutics Corporation (Modalis) (Tokyo Stock Exchange: 4883) announced that it has entered into an agreement with Ginkgo Bioworks (Ginkgo) to join the Ginkgo Technology Network. This strategic alliance will enable Ginkgo’s global customers in the cell and gene therapy fields…
Shionogi B.V., the European arm of Shionogi & Co., Ltd., has revealed that the European Commission has granted Orphan Medicinal Product designation to zatolmilast (BPN14770), an investigational treatment for Fragile X syndrome (FXS), a prominent cause of inherited intellectual disability…
AbbVie (NYSE: ABBV) has revealed interim findings from an ongoing Phase 3 extension study, spanning 156 weeks, investigating the sustained safety and tolerability of oral atogepant for migraine prevention in individuals with chronic or episodic migraine. The analysis indicates that…
In a recent announcement, the World Health Organization (WHO) has provided updates regarding the simultaneous treatment of drug-resistant tuberculosis (TB) and hepatitis C (HCV). The latest evidence suggests that administering treatment for HCV alongside multi-drug resistant or rifampicin-resistant TB (MDR/RR-TB)…
Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) has announced its plans to unveil the financial results for the first quarter of 2024 on Wednesday, May 8, 2024, at 7:00 a.m. ET through a press release. Subsequent to the release,…
ICON, a globally renowned healthcare intelligence and clinical research organization, has announced that its Chief Financial Officer, Brendan Brennan, will be stepping down from his position in the fourth quarter of this year to pursue an opportunity outside the CRO…
